Skip to main content

Adaptimmune Therapeutics PLC (ADAP)

NASDAQ: ADAP · Delayed Price · USD
3.83
-0.06 (-1.54%)
At close: Dec 8, 2021 4:00 PM
3.95
0.12 (3.13%)
After-hours:Dec 8, 2021 7:05 PM EST
Market Cap598.26M
Revenue (ttm)6.23M
Net Income (ttm)-155.85M
Shares Out156.20M
EPS (ttm)-1.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,201,134
Open3.95
Previous Close3.89
Day's Range3.77 - 3.95
52-Week Range3.37 - 7.34
Beta1.99
AnalystsHold
Price Target9.17 (+139.4%)
Earnings DateNov 4, 2021

About ADAP

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and n...

IndustryBiotechnology
IPO DateMay 6, 2015
Employees462
Stock ExchangeNASDAQ
Ticker SymbolADAP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ADAP stock is "Hold." The 12-month stock price forecast is 9.17, which is an increase of 139.43% from the latest price.

Price Target
$9.17
(139.43% upside)
Analyst Consensus: Hold

News

8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022

These eight stocks could rebound nicely over the next year and beyond.

1 day ago - The Motley Fool

Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November

A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.

Other symbols:AGENOCGN
4 days ago - The Motley Fool

Why Adaptimmune Therapeutics Stock Is Crashing Today

Investor sentiment has turned against this promising cell therapy company.

1 week ago - The Motley Fool

2 Falling-Knife Stocks Actually Worth Buying Right Now

Adaptimmune Therapeutics and Agenus are having a tough go of it in the final quarter of 2021.

Other symbols:AGEN
2 weeks ago - The Motley Fool

Translational Data at SITC 2021 from Adaptimmune's Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Co...

- Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells -

3 weeks ago - GlobeNewsWire

Adaptimmune Bullish On Meeting Endpoint For Soft Tissue Cancer Trial

Adaptimmune Therapeutics plc (NASDAQ: ADAP) will report updated data from its SPEARHEAD-1 Phase 2 trial with afamitresgene autoleucel (afami-cel, ADP-A2M4) in patients with advanced synovial sarcoma or ...

3 weeks ago - Benzinga

Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS a...

- SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year -

3 weeks ago - GlobeNewsWire

2 Biotech Companies That Might Be on Pfizer's Radar Right Now

These two small-cap cancer companies would be a perfect fit for Pfizer.

Other symbols:PFE
1 month ago - The Motley Fool

Adaptimmune Therapeutics: Q3 Earnings Insights

Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

1 month ago - Benzinga

Adaptimmune Reports Third Quarter Financial Results and Business Update

- Strategic Collaboration Agreement with Genentech has started after expiration of HSR waiting periods; Adaptimmune set to receive $150 million upfront payment -

1 month ago - GlobeNewsWire

Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and pr...

1 month ago - GlobeNewsWire

2 Top Healthcare Stocks That Could Be Bought Out in 2022

These two novel-drug makers could be top takeover targets next year.

Other symbols:CRSP
1 month ago - The Motley Fool

Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings

- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS -

2 months ago - GlobeNewsWire

3 Biotech Stocks That Could Make You Filthy Rich

These three low-priced cancer stocks could be grossly undervalued.

Other symbols:CRVSVSTM
2 months ago - The Motley Fool

Can Adaptimmune (ADAP) Run Higher on Strong Earnings Estimate Revisions?

Adaptimmune (ADAP) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

2 months ago - Zacks Investment Research

Why Adaptimmune Therapeutics Was Sinking This Week

Profit-taking seemed to be the general dynamic behind the biotech's 14% slide.

2 months ago - The Motley Fool

Adaptimmune Shares Encouraging Data From Solid Tumor Trial

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced updated data from its Phase 1 SURPASS trial in multiple solid tumors evaluating ADP-A2M4CD8. ADP-A2M4CD8 is a next-generation T-cell therapy eng...

2 months ago - Benzinga

Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and...

- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers -

2 months ago - GlobeNewsWire

Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies

Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.

3 months ago - Zacks Investment Research

Why Adaptimmune Therapeutics Stock Is Bolting Higher Today

A major licensing deal with cancer giant Roche is pushing the biotech's shares higher this morning.

3 months ago - The Motley Fool

Adaptimmune Stock Moves Higher On Cancer Deal With Genentech

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC: RHHBY), to develop and commercialize allogeneic cell the...

3 months ago - Benzinga

Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targe...

- Combining both companies' cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the de...

3 months ago - GlobeNewsWire

Adaptimmune (ADAP) Presents Data on Liver Cancer Candidate

Adaptimmune (ADAP) announces encouraging data from an early-stage study on liver cancer patients from its cell therapy candidate.

3 months ago - Zacks Investment Research

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff -

3 months ago - GlobeNewsWire

Why Adaptimmune Therapeutics Stock Is Spiking Today

The hunt for the next biotech buyout play is apparently underway.

3 months ago - The Motley Fool